Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children
Clinical/Medical (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 11, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
What are the benefits and risks of different corticosteroid treatments delivered intravenously for the prevention of bronchopulmonary dysplasia in infants born prematurely?
Wednesday, April 3, 2024 (Source: Cochrane News and Events)
Source: Cochrane News and Events - April 3, 2024 Category: Information Technology Authors: Paolo Rosati Source Type: news
Should You Give Injectables a Shot for Osteoarthritis Pain?
A number of injectables, including corticosteroids and hyaluronic acid, are available to help treat painful knee osteoarthritis. (Source: WebMD Health)
Source: WebMD Health - April 1, 2024 Category: Consumer Health News Source Type: news
Oral Corticosteroids Ease Preschoolers' Acute Wheeze
(MedPage Today) -- Oral corticosteroids helped reduce wheeze severity and length of hospital stay in children experiencing acute preschool wheeze, a pooled analysis of patient-level randomized trial data showed.
The medication reduced wheezing... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 29, 2024 Category: Pediatrics Source Type: news
Comparative analysis of CRASH and IMPACT in predicting the outcome of 340 patients with traumatic brain injury - An T, Dong Z, Li X, Ma Y, Jin J, Li L, Xu L.
BACKGROUND: Both the International Mission for Prognosis and Analysis of Clinical Trials (IMPACT) and the Corticosteroid randomization after significant head injury (CRASH) models are globally acknowledged prognostic algorithms for assessing traumatic brai... (Source: SafetyLit)
Source: SafetyLit - March 28, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Promising Phase 3 Data on DMD Hopeful Givinostat Promising Phase 3 Data on DMD Hopeful Givinostat
Treatment with the investigational agent givinostat has the potential to delay disease progression when added to corticosteroid treatment in ambulatory boys with Duchenne muscular dystrophy.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 21, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
The effect of oral analgesic premedication on the success rate of inferior alveolar nerve block for teeth with irreversible pulpitis: A randomized clinical trial
Conclusions:
Premedication with pharmapain (an anti-inflammatory agent) and
dexamethasone (a corticosteroid) does not enhance the success rate of
the IANB technique in mandibular molars with irreversible pulpitis
compared to placebo. However, the use of dexamethasone was significantly
more effective than pharmapain in reducing pain severity at inserting
endodontic files. (Source: Dental Technology Blog)
Source: Dental Technology Blog - March 19, 2024 Category: Dentistry Source Type: news
The Most Exciting New Advances in Managing COPD
The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, is the world’s preeminent COPD research and advocacy organization. Founded in 1997 in collaboration with the U.S. National Institutes of Health and the World Health Organization, one of GOLD’s stated aims is to “improve prevention and treatment of this lung disease.”
In its 2023 global strategy report, GOLD changed its definition of COPD—which many in the profession viewed as overdue. Specifically, the new definition emphasized the heterogeneity of COPD in terms of its underlying drivers and long-term disease course.
[ti...
Source: TIME: Health - March 18, 2024 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized freelance Source Type: news
New Expert Recommendations on Pediatric Vitiligo Care New Expert Recommendations on Pediatric Vitiligo Care
New consensus-based guidelines support the use of topical calcineurin inhibitors, topical corticosteroids, and topical JAK inhibitors for treatment.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 14, 2024 Category: Internal Medicine Tags: Pediatrics Source Type: news
Computational Simulations Shed Light on Factors Affecting Nasal Spray Distribution
In this series of simulations, researchers in CDER and external collaborators studied how different factors may affect corticosteroid nasal deposition (where the drug particles land in the nose) and, relatedly, nasal distribution (where the drug particles ultimately ‘reside’). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 12, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Why You Suddenly Have Allergies
When Dr. Gailen Marshall was training to become a physician, he was taught that allergies were a kid thing. “Back in the day, the allergist’s office was full of children,” says Marshall, who is the president of the American College of Allergy, Asthma, and Immunology. “If you ever thought about doing allergy testing or allergy shots in someone older than 40, that’s because you were just a money-grubbing doctor.”
A lot has changed since then. In 2021, about a quarter of U.S. adults reported seasonal allergies, compared to 19% of children.
[time-brightcove not-tgx=”true”]
...
Source: TIME: Health - March 12, 2024 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Source Type: news
Asthma Control Better With Biologic-Corticosteroid Combo
(MedPage Today) -- WASHINGTON -- Adding dupilumab (Dupixent) to a medium-dose inhaled corticosteroid (ICS) routine helped lower asthma exacerbations and improved both lung function and asthma control, according to a post-hoc analysis of the LIBERTY... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 26, 2024 Category: Allergy & Immunology Source Type: news
Drug Trials Snapshots: AGAMREE
AGAMREE is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 16, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Eohilia for Eosinophilic Esophagitis
FRIDAY, Feb. 16, 2024 -- The U.S. Food and Drug Administration has approved Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis (EoE).
The oral corticosteroid therapy is approved for individuals... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 16, 2024 Category: Pharmaceuticals Source Type: news
FDA Approves First Oral Option for Eosinophilic Esophagitis
(MedPage Today) -- The FDA approved budesonide oral suspension (Eohilia) for adults and children ages 11 years and older with eosinophilic esophagitis (EoE), drugmaker Takeda announced.
Approval of the 12-week course of corticosteroids, delivered... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 12, 2024 Category: Allergy & Immunology Source Type: news
